Figure 4.

Influence of keratinocyte-conditioned medium components and other factors on Wnt10b mRNA expression in human dermal papilla cells (hDPCs). (A, B): Wnt10b mRNA expression of hDPCs cultured in SF-DMEM with supplementation of each factor for 2 (A) or 48 (B) hours. Data are shown as fold change compared with control medium (SF-DMEM) (n = 3). **, Significant differences from control medium (p < .01). (C, D): Also shown is Wnt10b mRNA expression of hDPCs cultured in DMEM/10% FBS with supplementation of each factor for 2 (C) or 48 (D) hours. Data are shown as fold change compared with control medium (10% DMEM) (n = 3). **, Significant differences from control media (p < .01). Supplements and concentrations used were as follows: aFGF (100 ng/ml), bFGF (100 ng/ml), IL-1β (100 ng/ml), IL-6 (100 ng/ml), IL-8 (100 ng/ml), VEGF (100 ng/ml), PDGF-BB (100 ng/ml), NGF (100 ng/ml), HB-EGF (100 ng/ml), MIP (100 ng/ml), MCP (100 ng/ml), IGF (100 ng/ml), ENA (100 ng/ml), GROa (100 ng/ml), VD₃ (100 nM), VC (100 μM), CS (100 μM), atRA (10 nM), 17β-estradiol (10 nM), and DHT (10 nM). Abbreviations: aFGF, acidic fibroblast growth factor; atRA, all-trans retinoic acid; bFGF, basic fibroblast growth factor; CS, cholesterol sulfate; DHT, dihydrotestosterone; ENA-78, epithelial cell-derived neutrophil-activating peptide-78; FBS, fetal bovine serum; GROa, growth-related oncogene-α; HB-EGF, heparin-binding epidermal growth factor-like growth factor; IGF-1, insulin-like growth factor 1; IL, interleukin; MCP1, monocyte chemotactic protein 1; MIP3a, macrophage inflammatory protein-3α; NGF, nerve growth factor; PDGF-BB, platelet-derived growth factor-BB; SF-DMEM, serum-free Dulbecco's modified Eagle's medium; VC, ascorbic acid; VD₃, 1α,25-dihydroxyvitamin D₃; VEGF, vascular endothelial growth factor.